These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22289849)

  • 1. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats.
    Auclair D; Finnie J; Walkley SU; White J; Nielsen T; Fuller M; Cheng A; O'Neill CA; Hopwood JJ
    Pediatr Res; 2012 Jan; 71(1):39-45. PubMed ID: 22289849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen.
    Auclair D; Finnie J; White J; Nielsen T; Fuller M; Kakkis E; Cheng A; O'Neill CA; Hopwood JJ
    Mol Genet Metab; 2010 Feb; 99(2):132-41. PubMed ID: 19896877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
    Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
    Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI.
    Auclair D; Hopwood JJ; Lemontt JF; Chen L; Byers S
    Mol Genet Metab; 2007 Aug; 91(4):352-61. PubMed ID: 17544310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
    Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
    Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.
    Muñoz-Rojas MV; Horovitz DD; Jardim LB; Raymundo M; Llerena JC; de Magalhães Tde S; Vieira TA; Costa R; Kakkis E; Giugliani R
    Mol Genet Metab; 2010 Apr; 99(4):346-50. PubMed ID: 20036175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats.
    Turner CT; Hopwood JJ; Bond CS; Brooks DA
    Mol Genet Metab; 1999 Jul; 67(3):194-205. PubMed ID: 10381327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry.
    Crawley A; Ramsay SL; Byers S; Hopwood J; Meikle PJ
    Pediatr Res; 2004 Apr; 55(4):585-91. PubMed ID: 14711884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
    Harmatz P; Giugliani R; Schwartz I; Guffon N; Teles EL; Miranda MC; Wraith JE; Beck M; Arash L; Scarpa M; Yu ZF; Wittes J; Berger KI; Newman MS; Lowe AM; Kakkis E; Swiedler SJ;
    J Pediatr; 2006 Apr; 148(4):533-539. PubMed ID: 16647419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease.
    Di Natale P; Villani GR; Parini R; Scarpa M; Parenti G; Pontarelli G; Grosso M; Sersale G; Tomanin R; Sibilio M; Barone R; Fiumara A
    Biotechnol Appl Biochem; 2008 Mar; 49(Pt 3):219-23. PubMed ID: 17672828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB.
    Drugs R D; 2005; 6(5):312-5. PubMed ID: 16128602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval.
    Auclair D; Hein LK; Hopwood JJ; Byers S
    Pediatr Res; 2006 Apr; 59(4 Pt 1):538-43. PubMed ID: 16549525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.
    Harmatz P
    Turk J Pediatr; 2010; 52(5):443-9. PubMed ID: 21434527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase.
    Harmatz P; Giugliani R; D Schwartz IV; Guffon N; Teles EL; Miranda MCS; Wraith JE; Beck M; Arash L; Scarpa M; Ketteridge D; Hopwood JJ; Plecko B; Steiner R; Whitley CB; Kaplan P; Yu ZF; Swiedler SJ; Decker C;
    Mol Genet Metab; 2008 Aug; 94(4):469-475. PubMed ID: 18502162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study.
    Harmatz P; Kramer WG; Hopwood JJ; Simon J; Butensky E; Swiedler SJ;
    Acta Paediatr Suppl; 2005 Mar; 94(447):61-8; discussion 57. PubMed ID: 15895715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up to five years experience with 11 mucopolysaccharidosis type VI patients.
    Brands MM; Oussoren E; Ruijter GJ; Vollebregt AA; van den Hout HM; Joosten KF; Hop WC; Plug I; van der Ploeg AT
    Mol Genet Metab; 2013 May; 109(1):70-6. PubMed ID: 23523338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI.
    Horovitz DD; Magalhães TS; Acosta A; Ribeiro EM; Giuliani LR; Palhares DB; Kim CA; de Paula AC; Kerstenestzy M; Pianovski MA; Costa MI; Santos FC; Martins AM; Aranda CS; Correa Neto J; Holanda GB; Cardoso L; da Silva CA; Bonatti RC; Ribeiro BF; Rodrigues Mdo C; Llerena JC
    Mol Genet Metab; 2013 May; 109(1):62-9. PubMed ID: 23535281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): a single dose of galsulfase further reduces urine glycosaminoglycans after hematopoietic stem cell transplantation.
    Whitley CB; Utz JR
    Mol Genet Metab; 2010 Dec; 101(4):346-8. PubMed ID: 20800524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feline mucopolysaccharidosis type VI: correction of glycosaminoglycan storage in myoblasts by retrovirus-mediated transfer of the feline N-acetylgalactosamine 4-sulfatase gene.
    Yogalingam G; Bielicki J; Hopwood JJ; Anson DS
    DNA Cell Biol; 1997 Oct; 16(10):1189-94. PubMed ID: 9364929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
    Harmatz P; Whitley CB; Waber L; Pais R; Steiner R; Plecko B; Kaplan P; Simon J; Butensky E; Hopwood JJ
    J Pediatr; 2004 May; 144(5):574-80. PubMed ID: 15126989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.